GSK acquires RAPT Therapeutics for $2.2bn

Core Viewpoint - GSK is acquiring RAPT Therapeutics for up to $2.2 billion to enhance its immunology portfolio, focusing on food allergy treatments [1][2]. Group 1: Acquisition Details - GSK will pay $58.00 per share for RAPT, resulting in an aggregate equity value of approximately $2.2 billion, significantly higher than RAPT's closing stock value of $35.10 on January 16 [1]. - The acquisition includes global commercial rights to ozureprubart, a long-acting anti-immunoglobulin E (IgE) prophylactic food allergy candidate, outside of specific Asian markets [2]. Group 2: Product Potential - Ozureprubart is currently in Phase IIb clinical trials and could become a "best-in-class" medication if approved, due to its once-quarterly dosing schedule, unlike other therapies that require more frequent dosing [3]. Group 3: Strategic Focus - GSK is emphasizing immunology as a key growth area, having previously engaged in a $12 billion deal with Hengrui Pharma for immunology and oncology assets [4]. - The company also established a five-year £50 million ($54.3 million) R&D agreement with the University of Cambridge to develop new treatments for immune dysfunction [5]. Group 4: Industry Context - The pharmaceutical industry is facing a significant patent cliff, with potential losses of $230 billion in the US market from 2025 to 2030, prompting companies to seek new growth avenues [6]. - GSK's Chief Scientific Officer highlighted the use of AI-driven early-stage R&D to strengthen its pipeline and mitigate losses from drug patent expirations [7].